Loading...
Little randomized trial evidence exists to support use of rituximab for myasthenia gravis (MG). In this trial, adults with non-thymomatous generalized MG, symptoms for <12 months, and a Quantitative Myasthenia Gravis (QMG) score of 6 or more (out of 39 points, with higher scores representing more-severe disease) were randomized without stratification to a single infusion of rituximab 500 mg (n=25) or placebo (n=22). Patients taking prednisolone >40 mg daily or other steroid-sparing immunosuppressants were excluded. Only two participants did not have acetylcholine receptor (AChR) antibodies. There were baseline differences between the groups: Rituximab recipients were older than placebo recipients (mean, 67 years vs. 58 years), had lower ACh…